Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Payables: 2011-2025

Historic Payables for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $24.0 million.

  • Adma Biologics' Payables rose 49.94% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.6 million, marking a year-over-year increase of 50.08%. This contributed to the annual value of $20.2 million for FY2024, which is 29.11% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Payables is $24.0 million, which was down 19.31% from $29.8 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Payables ranged from a high of $112.2 million in Q1 2021 and a low of $6.2 million during Q2 2021.
  • Moreover, its 3-year median value for Payables was $16.0 million (2024), whereas its average is $17.6 million.
  • Within the past 5 years, the most significant YoY rise in Adma Biologics' Payables was 1,125.41% (2021), while the steepest drop was 88.81% (2021).
  • Quarterly analysis of 5 years shows Adma Biologics' Payables stood at $12.4 million in 2021, then increased by 6.43% to $13.2 million in 2022, then rose by 18.38% to $15.7 million in 2023, then rose by 29.11% to $20.2 million in 2024, then surged by 49.94% to $24.0 million in 2025.
  • Its Payables stands at $24.0 million for Q3 2025, versus $29.8 million for Q2 2025 and $20.6 million for Q1 2025.